Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity
摘要:
We report the development and characterization of compound 22 (MK-5046), a potent, selective small molecule agonist of BRS-3 (bombesin receptor subtype-3). In pharmacological testing using diet-induced obese mice, compound 22 caused mechanism-based, dose-dependent reductions in food intake and body weight.
Substituted imidazole as bombesin receptor subtype-3 modulators
申请人:Merck Sharp & Dohme Corp.
公开号:US08193228B2
公开(公告)日:2012-06-05
Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS
申请人:Merck & Co., Inc.
公开号:EP2091937A2
公开(公告)日:2009-08-26
US8193228B2
申请人:——
公开号:US8193228B2
公开(公告)日:2012-06-05
[EN] SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS<br/>[FR] IMIDAZOLES SUBSTITUES UTILISES COMME MODULATEURS DU SOUS-TYPE 3 DU RÉCEPTEUR DE LA BOMBÉSINE
申请人:MERCK & CO INC
公开号:WO2008051406A2
公开(公告)日:2008-05-02
[EN] Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes. [FR] L'invention concerne certains nouveaux imidazoles substitués qui sont des ligands du récepteur de la bombésine humaine et, en particulier, des ligands sélectifs du sous-type 3 du récepteur de la bombésine humaine (BRS-3). Lesdits imidazoles substitués sont utiles dans le traitement, le contrôle et la prévention de maladies et de troubles réagissant à la modulation du BRS-3, comme l'obésité et le diabète.
Substituted inmidazoles as bombesin receptor subtype-3 modulators
申请人:Chen David
公开号:US20100022598A1
公开(公告)日:2010-01-28
Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.